Clinical trial
Safety and Efficacy of PHP in the Treatment of Shock Associated With Systemic…
NCT00021502 · Apex Bioscience, Industry · Completed
Key facts
| NCT number | NCT00021502 |
|---|---|
| Title | Safety and Efficacy of PHP in the Treatment of Shock Associated With Systemic Inflammatory Response Syndrome (SIRS) |
| Official title | A Phase 3, Multi-Center, Randomized, Placebo Controlled Study of PHP When Administered by Continuous Infusion in Patients With Shock Associated With Systemic Inflammatory Response Syndrome (SIRS) |
| Lead sponsor | Apex Bioscience, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Shock, Systemic Inflammatory Response Syndrome |
| Intervention type | Drug |
| Interventions | pyridoxalated hemoglobin polyoxyethylene conjugate (PHP) |
| Enrollment | 1,000 |
| Start date | Mar 1, 2001 |
| Primary completion | Aug 1, 2003 |
| Completion | May 1, 2004 |
| First posted | Jul 20, 2001 |
| Last update posted | Aug 14, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: